Clinical Research
Copyright ©2007 Baishideng Publishing Group Inc.
World J Gastroenterol. Oct 21, 2007; 13(39): 5238-5244
Published online Oct 21, 2007. doi: 10.3748/wjg.v13.i39.5238
Table 4 Clinical characteristics of patients developing malignant disorders during IFX treatment
DiseaseUlcerative colitisCrohn’s diseaseCrohn’s disease
Disease duration (yr)2233
Site of diseaseLeft colonIleum-colonIleum-colon
Type of neoplasia (TNM)Breast cancer (T2mN3M0)Gastric cancer (T2aN0M0)Endometrial cancer (T1cN0M0)
Concomitant medicationAzathioprineAzathioprine/cyprofloxacine/metronidazoleAzathioprine/ cyprofloxacine/ metronidazole
N. IFX infusions13610
Months since first IFX infusion212414